Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors-Reference-Cited by-同舟云学术

Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors

Published:2019-03-19 Issue:7 Volume:62 Page:3707-3721
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Huang Yi-You¹^ORCID,Yu Yan-Fa¹,Zhang Chen¹,Chen Yiping¹,Zhou Qian¹,Li Zhuoming¹,Zhou Sihang¹,Li Zhe¹,Guo Lei¹,Wu Deyan¹^ORCID,Wu Yinuo¹^ORCID,Luo Hai-Bin¹^ORCID

Affiliation:

1. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Ministry of Education of the People's Republic of China

Guangdong Province Higher Vocational Colleges & Schools Pearl River Scholar Funded Scheme

Pearl River S&T Nova program of Guangzhou

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00224

Reference65 articles.

1. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

2. Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use

3. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues

4. Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia

5. Current Landscape of Phosphodiesterase 10A (PDE10A) Inhibition

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Optimization of 4-(Imidazo[1,2-a]pyrimidin-3-yl)thiazol-2-amine Derivatives as Novel Phosphodiesterase 4 Inhibitors;2024-08-30

2. Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis;Bioorganic Chemistry;2024-08

3. Totally Caged Type I Pro‐Photosensitizer for Oxygen‐Independent Synergistic Phototherapy of Hypoxic Tumors;Advanced Science;2024-06-17

4. Discovery of highly potent phosphodiesterase-1 inhibitors by a combined-structure free energy perturbation approach;Acta Pharmaceutica Sinica B;2024-06

5. Discovery of novel selective phosphodiesterase‑1 inhibitors for the treatment of acute myelogenous leukemia;Bioorganic Chemistry;2024-03